Cargando…

Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: Despite massive research efforts, the mortality of pancreatic ductal adenocarcinoma is still high. In recent years, the tumor microenvironment has been revealed to play a key role in carcinogenesis. Therefore, our study aimed to further characterize the family of cancer-associated fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knipper, Karl, Damanakis, Alexander I., Zhao, Yue, Bruns, Christiane J., Schmidt, Thomas, Popp, Felix C., Quaas, Alexander, Lyu, Su Ir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093167/ https://www.ncbi.nlm.nih.gov/pubmed/37046710 http://dx.doi.org/10.3390/cancers15072049

Ejemplares similares

Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival
por: Lyu, Su Ir, et al.
Publicado: (2023)

High NANOG expression correlates with worse patients’ survival in esophageal adenocarcinoma
por: Knipper, Karl, et al.
Publicado: (2023)

X-linked inhibitor of apoptosis protein is a prognostic marker for a favorable outcome in three identified subsets in resectable adenocarcinoma of the pancreas
por: Knipper, Karl, et al.
Publicado: (2022)

Cancer-Associated Fibroblast Heterogeneity and Its Influence on the Extracellular Matrix and the Tumor Microenvironment
por: Knipper, Karl, et al.
Publicado: (2023)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

Copy-number-gain of telomerase reverse transcriptase (hTERT) is associated with an unfavorable prognosis in esophageal adenocarcinoma
por: Lyu, Su Ir, et al.
Publicado: (2023)

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
por: Gebauer, Florian, et al.
Publicado: (2021)

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
por: Gebauer, Florian, et al.
Publicado: (2023)

Proposal for a definition of "Oligometastatic disease in pancreatic cancer"
por: Damanakis, Alexander I., et al.
Publicado: (2019)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma
por: Damanakis, Alexander, et al.
Publicado: (2022)

Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma
por: Katsuta, Eriko, et al.
Publicado: (2020)

Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Salmiheimo, Aino, et al.
Publicado: (2016)

Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
por: Damanakis, Alexander I., et al.
Publicado: (2022)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019)

Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival
por: Loeser, Heike, et al.
Publicado: (2020)

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
por: Zhang, Tianyi, et al.
Publicado: (2022)

Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy
por: Collisson, Eric A., et al.
Publicado: (2011)

Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma
por: Roy, Shikha, et al.
Publicado: (2021)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes
por: Schlitter, Anna Melissa, et al.
Publicado: (2017)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma
por: Vay, Christian, et al.
Publicado: (2022)

First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report
por: Buchner, Denise, et al.
Publicado: (2018)

Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma
por: Wilson, Gregory C., et al.
Publicado: (2023)

Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma
por: Distler, Marius, et al.
Publicado: (2013)

An Immunological Glance on Pancreatic Ductal Adenocarcinoma
por: Melzer, Michael Karl, et al.
Publicado: (2020)

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
por: de Santiago, Ines, et al.
Publicado: (2019)

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
por: Espiau-Romera, Pilar, et al.
Publicado: (2020)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Subtypes of pancreatic stellate cells and distant metastasis of pancreatic ductal adenocarcinoma
por: Fan, Yuhui, et al.
Publicado: (2020)

Cancer-Associated Fibroblasts’ Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma
por: Awaji, Mohammad, et al.
Publicado: (2019)

Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma
por: Schiffmann, Lars M., et al.
Publicado: (2020)

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis
por: Simon, Adrian Georg, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5nglmftocnt0ur7km868uk92it